MedTrace Logo

Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome

NCT05312463 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2022-04-05

No results posted yet for this study

Summary

Overlapping gastrointestinal symptoms of functional gastrointestinal diseases (FGIDs) is an internationally recognized problem in modern medical diagnosis and treatment. Such patients show more physical symptoms and worse quality of life, resulting in a huge economic burden. At present, FGIDs gastrointestinal symptoms overlap, lack of effective and systematic treatment, and the treatment goal is to improve symptoms.The study plans to carry out a multi center and large sample RCT clinical study of Tongjiang granule in the treatment of overlapping gastrointestinal symptoms of non erosive reflux disease(NERD)and epigastric pain syndrome（EPS, so as to provide high-level evidence-based evidence for the treatment of overlapping symptoms of FGIDs and form a diagnosis and treatment scheme that can be popularized.

Conditions

  • Gastroesophageal Reflux
  • Functional Dysphonia

Interventions

DRUG

Tongjiang granule

Tongjiang granules, 1 bag / time, 3 times / day.

DRUG

Tongjiang granule simulant

Tongjiang granule simulant,1 bag / time, 3 times / day.

Sponsors & Collaborators

  • First Affiliated Hospital of Heilongjiang Chinese Medicine University

    collaborator OTHER

  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

    collaborator UNKNOWN

  • Liuzhou Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-26
Primary Completion
2023-10-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312463 on ClinicalTrials.gov